Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- Creator: Hughes, Timothy P. , Branford, Susan , Cooney, Julian , Leahy, Michael F. , Rowlings, Philip , Catalano, John , Hertzberg, Mark , Filshie, Robin , Mills, Anthony K. , Fay, Keith , Durrant, Simon , Januszewicz, Henry , White, Deborah L. , Joske, David , Underhill, Craig , Dunkley, Scott , Lynch, Kevin , Grigg, Andrew , Reynolds, John , Koelmeyer, Rachel , Seymour, John F. , Taylor, Kerry , Arthur, Chris , Schwarer, Anthony K. , Morton, James
- Resource Type: journal article
- Date: 2008
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (ST1571) compared with wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant
- Creator: Frost, Michelle J. , Ferrao, Petranel T. , Hughes, Timothy P. , Ashman, Leonie K.
- Resource Type: journal article
- Date: 2002